About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 453606, 11 pages
http://dx.doi.org/10.1155/2013/453606
Research Article

Chromogenic In Situ Hybridization and p16/Ki67 Dual Staining on Formalin-Fixed Paraffin-Embedded Cervical Specimens: Correlation with HPV-DNA Test, E6/E7 mRNA Test, and Potential Clinical Applications

1Cytopathology Unit, Experimental and Clinical Sciences Department, “G. d'Annunzio” University of Chieti-Pescara, Via dei Vestini, 66100 Chieti, Italy
2Surgical Pathology Unit, “SS Annunziata” Hospital, ASL2 Abruzzo, Chieti, Italy

Received 16 July 2013; Revised 20 September 2013; Accepted 30 September 2013

Academic Editor: Oronza Antonietta Botrugno

Copyright © 2013 Roberta Zappacosta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Zappacosta and S. Rosini, “Cervical cancer screening: from molecular basis to diagnostic practice, going through new technologies,” Technology in Cancer Research and Treatment, vol. 7, no. 3, pp. 161–174, 2008. View at Scopus
  2. J. Cuzick, C. Clavel, K. Petry et al., “Overview of the European and North American studies on HPV testing in primary cervical cancer screening,” International Journal of Cancer, vol. 119, no. 5, pp. 1095–1101, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Cuzick, M. Arbyn, R. Sankaranarayanan et al., “Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries,” Vaccine, vol. 26, no. 10, pp. K29–K41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Giorgi Rossi, M. Benevolo, A. Vocaturo, et al., “Prognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study,” PLOS One, vol. 8, no. 2, pp. 54–62, 2013.
  5. M. Guo, Y. Gong, M. Deavers et al., “Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma,” Journal of Clinical Microbiology, vol. 46, no. 1, pp. 274–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. M. Dabić, L. Hlupić, D. Babić, S. Jukić, and S. Seiwerth, “Comparison of polymerase chain reaction and catalyzed signal amplification in Situ hybridization methods for human papillomavirus detection in paraffin-embedded cervical preneoplastic and neoplastic lesions,” Archives of Medical Research, vol. 35, no. 6, pp. 511–516, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. M. F. Evans, S. L. Mount, B. G. Beatty, and K. Cooper, “Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia,” Modern Pathology, vol. 15, no. 12, pp. 1339–1347, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. J. D. Meissner, “Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines,” Journal of General Virology, vol. 80, no. 7, pp. 1725–1733, 1999. View at Scopus
  9. K. U. Petry, D. Schmidt, S. Scherbring et al., “Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology,” Gynecologic Oncology, vol. 121, no. 3, pp. 505–509, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Schmidt, C. Bergeron, K. J. Denton, and R. Ridder, “p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study,” Cancer Cytopathology, vol. 119, no. 3, pp. 158–166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Tinelli, G. Leo, M. Pisanò et al., “HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions,” Current Pharmaceutical Biotechnology, vol. 10, no. 8, pp. 767–771, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. R. Landis and G. G. Koch, “The measurement of observer agreement for categorical data,” Biometrics, vol. 33, no. 1, pp. 159–174, 1977. View at Scopus
  13. E. R. DeLong, D. M. DeLong, and D. L. Clarke-Pearson, “Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach,” Biometrics, vol. 44, no. 3, pp. 837–845, 1988. View at Scopus
  14. P. J. F. Snijders, A. J. C. van den Brule, and C. J. L. M. Meijer, “The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity,” Journal of Pathology, vol. 201, no. 1, pp. 1–6, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Zappacosta, D. Caraceni, L. Ciccocioppo et al., “Is HPV-DNA testing a useful tool in predicting low-grade squamous intraepithelial lesion outcome? A retrospective longitudinal study,” International Journal of Immunopathology and Pharmacology, vol. 23, no. 1, pp. 317–326, 2010. View at Scopus
  16. W. Qu, G. Jiang, Y. Cruz et al., “PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems,” Journal of Clinical Microbiology, vol. 35, no. 6, pp. 1304–1310, 1997. View at Scopus
  17. M. Arbyn, P. Sasieni, C. J. L. M. Meijer, C. Clavel, G. Koliopoulos, and J. Dillner, “Chapter 9: clinical applications of HPV testing: a summary of meta-analyses,” Vaccine, vol. 24, supplement 3, pp. S78–S89, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. F. Evans and K. Cooper, “Human papillomavirus integration: detection by in situ hybridization and potential clinical application,” Journal of Pathology, vol. 202, no. 1, pp. 1–4, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Montag, T. J. F. Blankenstein, N. Shabani, A. Brüning, and I. Mylonas, “Evaluation of two commercialised in situ hybridisation assays for detecting HPV-DNA in formalin-fixed, paraffin-embedded tissue,” Archives of Gynecology and Obstetrics, vol. 284, no. 4, pp. 999–1005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. K. T. Kuo, C. H. Hsiao, C. H. Lin, L. Kuo, S. Huang, and M. Lin, “The biomarkers of human papillomavirus infection in tonsillar squamous cell carcinoma-molecular basis and predicting favorable outcome,” Modern Pathology, vol. 21, no. 4, pp. 376–386, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Luginbuhl, M. Sanders, and J. D. Spiro, “Prevalence, morphology, and prognosis of human papillomavirus in tonsillar cancer,” Annals of Otology, Rhinology and Laryngology, vol. 118, no. 10, pp. 742–749, 2009. View at Scopus
  22. M. F. Evans, H. A. Aliesky, and K. Cooper, “Optimization of biotinyl-tyramide-based in situ hybridization for sensitive background-free applications on formalin-fixed, paraffin-embedded tissue specimens,” BMC Clinical Pathology, vol. 3, no. 1, pp. 1–17, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. M. F. Evans, A. Matthews, D. Kandil, C. S. Adamson, W. E. Trotman, and K. Cooper, “Discrimination of “Driver” and “Passenger” HPV in tonsillar carcinomas by the polymerase chain reaction, chromogenic in situ hybridization, and p16INK4a immunohistochemistry,” Head and Neck Pathology, vol. 5, no. 4, pp. 344–348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. G. M. Clifford, J. S. Smith, M. Plummer, N. Muñoz, and S. Franceschi, “Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis,” British Journal of Cancer, vol. 88, no. 1, pp. 63–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Kraus, T. Molden, R. Holm et al., “Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas,” Journal of Clinical Microbiology, vol. 44, no. 4, pp. 1310–1317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. S. de Sanjosé, M. Diaz, X. Castellsagué et al., “Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis,” Lancet Infectious Diseases, vol. 7, no. 7, pp. 453–459, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Gallo, M. Bibbo, L. Bagella et al., “Study of viral integration of HPV-16 in young patients with LSIL,” Journal of Clinical Pathology, vol. 56, no. 7, pp. 532–536, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Murphy, M. Ring, C. C. B. B. Heffron et al., “p16INK4a, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer,” Journal of Clinical Pathology, vol. 58, no. 5, pp. 525–534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. S. Wang, M. Trunk, M. Schiffman et al., “Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica,” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 8, pp. 1355–1360, 2004. View at Scopus
  30. I. Tsoumpou, M. Arbyn, M. Kyrgiou et al., “p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis,” Cancer Treatment Reviews, vol. 35, no. 3, pp. 210–220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Klaes, T. Friedrich, D. Spitkovsky et al., “Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri,” International Journal of Cancer, vol. 92, no. 2, pp. 276–284, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Tsoumpou, G. Valasoulis, C. Founta et al., “High-risk human papillomavirus DNA test and p16INK4a in the triage of LSIL: a prospective diagnostic study,” Gynecologic Oncology, vol. 121, no. 1, pp. 49–53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. K. J. Denton, C. Bergeron, P. Klement, M. J. Trunk, T. Keller, and R. Ridder, “The sensitivity and specificity of p16INK4a cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL Pap cytology results,” American Journal of Clinical Pathology, vol. 134, no. 1, pp. 12–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. C. M. Martin and J. J. O'Leary, “Histology of cervical intraepithelial neoplasia and the role of biomarkers,” Best Practice & Research Clinical Obstetrics and Gynaecology, vol. 25, no. 5, pp. 605–615, 2011. View at Scopus
  35. J. L. Meyer, D. W. Hanlon, B. T. Andersen, O. F. Rasmussen, and K. Bisgaard, “Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: correlation with biopsy follow-up results,” Cancer, vol. 111, no. 2, pp. 83–92, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. M. del Pino, S. Garcia, V. Fusté et al., “Value of p16INK4a as a marker of progression/regression in cervical intraepithelial neoplasia grade 1,” American Journal of Obstetrics and Gynecology, vol. 201, no. 5, pp. 488e1–488e7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. L. M. Stewart, M. H. Einstein, W. K. Huh, et al., “Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors,” Journal of Lower Genital Tract Disease, vol. 17, pp. 1–27, 2013.